Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562950 | 0.85 | POLB (0.76) | POLBNPC1RAB9AHSD11B1TGFBR1 | |
| SCHEMBL16735591 | 0.81 | HSD11B1 (0.53) | POLBNPC1RAB9AHSD11B1TGFBR1 | |
| SCHEMBL4655512 | 0.78 | ALDH1A1 (0.50) | POLBCHRNA7MAPK14 | |
| SCHEMBL562370 | 0.78 | NPC1 (0.55) | POLBNPC1RAB9AHSD11B1TGFBR1 | |
| SCHEMBL562298 | 0.77 | NPC1 (0.54) | POLBNPC1RAB9AHSD11B1TGFBR1 | |
| Hydrochloric Acid SCHEMBL28060875 | 0.76 | ALDH1A1 (0.49) | POLBCHRNA7MAPK14 | |
| SCHEMBL2355162 | 0.76 | MAPK14 (0.62) | CHRNA7PDE4BMAPK14TRPM8 | |
| SCHEMBL2144311 | 0.75 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL7461010 | 0.74 | HSD11B1 (0.55) | NPC1RAB9AHSD11B1TGFBR1PDE4B | |
| SCHEMBL28488675 | 0.73 | ALDH1A1 (0.51) | POLBNPC1RAB9ACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | disclosed |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN2A, GRIN2B, SLC18A2 | POLB 2514/4885NPC1 1816/4885RAB9A 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.